CN113660927A - 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 - Google Patents

使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 Download PDF

Info

Publication number
CN113660927A
CN113660927A CN202080026162.6A CN202080026162A CN113660927A CN 113660927 A CN113660927 A CN 113660927A CN 202080026162 A CN202080026162 A CN 202080026162A CN 113660927 A CN113660927 A CN 113660927A
Authority
CN
China
Prior art keywords
composition
pvp
viscosity
arginine
lyophilized powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080026162.6A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·史罗埃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN113660927A publication Critical patent/CN113660927A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080026162.6A 2019-04-23 2020-04-22 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度 Pending CN113660927A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962837647P 2019-04-23 2019-04-23
US62/837,647 2019-04-23
PCT/US2020/029328 WO2020219550A1 (en) 2019-04-23 2020-04-22 The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations

Publications (1)

Publication Number Publication Date
CN113660927A true CN113660927A (zh) 2021-11-16

Family

ID=70614677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080026162.6A Pending CN113660927A (zh) 2019-04-23 2020-04-22 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度

Country Status (8)

Country Link
US (2) US12599669B2 (enExample)
EP (1) EP3958840A1 (enExample)
JP (1) JP7739182B2 (enExample)
CN (1) CN113660927A (enExample)
AU (1) AU2020263318B2 (enExample)
CA (1) CA3141857A1 (enExample)
MX (1) MX2021012782A (enExample)
WO (1) WO2020219550A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
CN113660927A (zh) 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度
CA3214867A1 (en) * 2021-04-09 2022-10-13 Courtney O'DELL Performance-enhancing excipients and methods of reducing viscosity and increasing stability of biologic formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
US20180237501A1 (en) * 2017-02-22 2018-08-23 Amgen Inc. Low-viscosity, high concentration evolocumab formulations and methods of making the same
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
JP4679822B2 (ja) 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
KR20110097772A (ko) 2008-11-17 2011-08-31 제넨테크, 인크. 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
AU2009339292B2 (en) 2008-12-10 2016-01-21 Allergan, Inc. Clostridial toxin pharmaceutical compositions
WO2016014408A1 (en) 2014-07-21 2016-01-28 Board Of Regents, The University Of Texas System Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
ES2964713T3 (es) * 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
CN106511997A (zh) 2015-09-15 2017-03-22 上海抗体药物国家工程研究中心有限公司 一种稳定的蛋白制剂
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
CN113660927A (zh) 2019-04-23 2021-11-16 安进公司 使用低分子量聚乙烯吡咯烷酮（pvp）降低高浓度蛋白质配制品的黏度

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
US20180237501A1 (en) * 2017-02-22 2018-08-23 Amgen Inc. Low-viscosity, high concentration evolocumab formulations and methods of making the same
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VOLKER BUHLER: "Polyvinylpyrrolidone Excipients for Pharmaceuticals", 31 December 2005, SPRING, pages: 10 - 11 *
WAYNE R. GOMBOTZ ET AL.: "The Stabilization of a Human IgM Monoclonal Antibody with Poly(vinylpyrrolidone)", PHARMACEUTICAL RESEARCH, vol. 11, no. 5, pages 625 *

Also Published As

Publication number Publication date
US20220226477A1 (en) 2022-07-21
EP3958840A1 (en) 2022-03-02
WO2020219550A1 (en) 2020-10-29
CA3141857A1 (en) 2020-10-29
JP7739182B2 (ja) 2025-09-16
JP2022529996A (ja) 2022-06-27
US12599669B2 (en) 2026-04-14
US20260199478A1 (en) 2026-07-16
MX2021012782A (es) 2021-11-25
AU2020263318A1 (en) 2021-10-21
AU2020263318B2 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
KR102397713B1 (ko) 안정한 액체 약제학적 제제
US12350340B2 (en) Viscosity reduction of highly concentrated protein formulations
AU2015257798C1 (en) Liquid formulation comprising GM-CSF neutralizing compound
CN105189559B (zh) 抗体制剂及其用途
JP7739182B2 (ja) 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン（ｐｖｐ）の使用
JP7467438B2 (ja) 抗ｒｓｖ抗体の製剤及びその使用方法
KR102106914B1 (ko) Gm-csf를 중화하는 화합물을 포함하는 액체 제제
CN111228479B (zh) 一种抗pd-l1抗体制剂
CA3178066A1 (en) Stable anti-clever-1 antibody formulation
WO2023040999A1 (zh) 包含pd-l1抗原结合片段的组合物及其用途
HK40109865A (en) Stable anti-osmr antibody formulation
US20250108109A1 (en) Formulations comprising fab-peg
WO2024129555A1 (en) Lyospheres containing programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CA2946230C (en) Liquid formulation comprising gm-csf neutralizing compound
EA040788B1 (ru) Жидкая композиция, содержащая соединение, нейтрализующее gm-csf
HK1235316A1 (en) Liquid formulation comprising gm-csf neutralizing compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination